Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-inflammatory effects of ziltivekimab assessed by imaging and cellular phenotyping
2022-004078-53Phase 2Active
- Sponsor
- Academic Medical Center
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atherosclerosis and cardiac morbidity comparing Ziltivekimab with Placebo (2 arms). Primary endpoints: Mean percentage change in coronary arteries TBRmax at 20 weeks and Mean percentage change in monocyte activation marker protein expression at 20 weeks. Started Aug 2023; status: active.
02
Drugs
ziltivekimab
03
Conditions
atherosclerosiscardiac morbidity
Beyond the preview
Go deeper on 2022-004078-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004078-53.